Europe Continuous Bioprocessing Market to be Worth $206.1 Million by 2030

Europe Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs) - Forecast to 2030

Meticulous Research– a leading global market research company, published a research report titled “Europe Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs) - Forecast to 2030”.

According to this latest publication from Meticulous Research, the Europe continuous bioprocessing market is expected to grow at a CAGR of 19.1% from 2023 to reach $206.1 million by 2030. The growth of this market is attributed to factors such as recent product launches and advances in the continuous bioprocessing space, gradual adoption of continuous manufacturing, and initiatives supporting the adoption of biopharmaceuticals. Furthermore, the shift towards bioprocessing 4.0 and the rising adoption of personalized medicines are expected to provide significant market growth opportunities.

However, the limitations of continuous bioprocessing may restrain the growth of this market. Additionally, manufacturers’ hesitation to shift from batch manufacturing to continuous manufacturing poses challenges to the market players.

Key Players

The key players operating in the Europe continuous bioprocessing market are 3M Company (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), Solida Biotech GmBH (Germany), Electrolab Biotech Limited (U.K.), Biowest (France), and Bionet (U.S.).

Europe Continuous Bioprocessing Market: Future Outlook

The Europe continuous bioprocessing market is segmented by Product (Filtration Systems and Consumables, Chromatography Systems and Consumables, Cell Culture Media, Buffers, and Reagents, Incubators and Shakers, Bioreactors, Centrifuges, Sterilizers, and Other Instruments and Consumables), Application (Commercial Applications [Monoclonal Antibodies (mAbs) Production, Cell and Gene Therapy Production, Vaccine Manufacturing, Plasma Fractionation, and Recombinant Protein Production], R&D), End User (Pharmaceutical and Biotechnology Companies, Contract Development and Manufacturing Organizations (CDMOS) and Contract Research Organizations (CROS), and Academic and Research Institutes), and Country. The study also evaluates industry competitors and analyzes the market at the country level.

In 2023, among the products, the filtration systems and consumables segment is estimated to account for the largest share of the market. Filtration is commonly used in biopharmaceutical processing for separating components. It is used in various downstream operations, such as clarification, filtration of intermediates, critical final filling applications, or upstream processing for sterilizing-grade filtration of cell culture media. The highest revenue share of this segment is attributed to the recurring use of filtration at every step in bioprocessing and technological advancements in filtration technologies.

In 2023, among the applications, the commercial applications segment is estimated to account for the largest share of the market. Growing initiatives supporting the adoption of biopharmaceuticals, rising biopharmaceutical manufacturing outsourcing, and accelerated developments in personalized therapies are likely to enhance the demand for bioprocessing systems and consumables for the commercial bioproduction of monoclonal antibodies (mAbs), vaccines, gene therapies, and recombinant protein-based therapies; thereby drive the continuous bioprocessing market for commercial application.

In 2023, among the end users, the pharmaceutical and biotechnology companies segment is estimated to account for the largest market share due to factors such as capacity expansions by biopharmaceutical manufacturers and the extensive adoption of biopharmaceutical processing equipment for bioproduction in the biopharmaceutical and biotechnology sectors.

Geographic Review

This research report provides a comprehensive analysis of the continuous bioprocessing market in Europe (Germany, the U.K., France, Spain, Italy, Switzerland, the Netherlands, Belgium, Denmark, Ireland, Rest of Europe). In 2023, Germany is expected to account for the largest share of the Europe continuous bioprocessing market. Factors such as the increasing vaccination programs, government investment in R&D, and rising need for biosimilars & personalized medicines supported the market's growth in Germany.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5605

Key questions answered in the report-

Which are the high-growth market segments in terms of product, application, end user, and country?
What was the historical market for continuous bioprocessing across Europe?
What are the market forecasts and estimates for the period 2023–2030?
What are the major drivers, restraints, opportunities, and challenges in the Europe continuous bioprocessing market?
Who are the major players in the Europe continuous bioprocessing market?
How is the competitive landscape, and who are the market leaders in the Europe continuous bioprocessing market?
What are the recent developments in the Europe continuous bioprocessing market?
What are the different strategies adopted by the major players in the Europe continuous bioprocessing market?
What are the geographical trends and high-growth countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research